Ropes & Gray represented R1 Therapeutics, a biopharmaceutical company focused on development of first-in-class therapeutics for patients with kidney disease, with an exclusive global license to develop and commercialize AP306 outside of Greater China from China-based Alebund Pharmaceuticals. The transaction was announced on March 17.
Proceeds from an oversubscribed $77.5 million Series A financing will fund R1’s global development program of AP306 in partnership with Alebund, including a Phase 2b clinical study as a monotherapy for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis.
The Ropes & Gray team included IP transactions partner Geoffrey Lin, and IP transactions associate Evan Tallmadge.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.